Starling Oncology, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value
Starling Oncology, Inc. (DFPH) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value of $1.68 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 · last filed 2026-08-06
- Starling Oncology, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2026-06-30 was $400.00K, a 36.61% decline year-over-year.
- Starling Oncology, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2026-03-31 was $1.28M, a 701.25% increase year-over-year.
- Starling Oncology, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2025-09-30 was $372.00K.
- Starling Oncology, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2025-06-30 was $631.00K.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 9 month |
|---|---|---|---|
| 2026-06-30 | $400.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $1.68M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $1.28M 10-Q · filed 2026-05-07 | ||
| 2025-09-30 | $372.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $1.00M derived: sum of 2 quarters · filed 2026-08-06 | $1.16M 10-Q · filed 2025-11-13 |
| 2025-06-30 | $631.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $791.00K 10-Q · filed 2026-08-06 | |
| 2025-03-31 | $160.00K 10-Q · filed 2026-05-07 | ||
| 2024-09-30 | -$71.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$685.00K derived: sum of 2 quarters · filed 2025-11-13 | $356.00K 10-Q · filed 2025-11-13 |
| 2024-06-30 | -$614.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $427.00K 10-Q · filed 2025-08-13 | |
| 2024-03-31 | $1.04M 10-Q · filed 2025-05-14 | ||
| 2023-09-30 | $1.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $1.33M derived: sum of 2 quarters · filed 2024-11-13 | $1.62M 10-Q · filed 2024-11-13 |
| 2023-06-30 | $152.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $433.00K 10-Q · filed 2024-08-13 | |
| 2023-03-31 | $281.00K 10-Q · filed 2024-05-14 | ||
| 2022-09-30 | $672.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $4.78M derived: sum of 2 quarters · filed 2023-11-08 | $6.98M 10-Q · filed 2023-11-08 |
| 2022-06-30 | $4.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $6.30M 10-Q · filed 2023-08-09 | |
| 2022-03-31 | $2.20M 10-Q · filed 2023-05-10 |